Compare Flex Ltd (FLEX) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flex Ltd vs Globus Medical Inc. Class A Common Stock — how do they compare? Flex Ltd trades at $98.9 (market cap $40.97B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Flex Ltd is far larger — about 4× Globus Medical Inc. Class A Common Stock's market cap, and Flex Ltd is more actively traded (5,533,554 versus 1,108,124). Which is the better fit depends on your goals — on Pluang, investors hold Flex Ltd for 6 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FLEX | GMED | |
|---|---|---|
Market Cap | $40.97B | $10.25B |
Volume | 5,533,554 | 1,108,124 |
Sector | Technology | Health |
52-Week High | $162.07 | $96.82 |
52-Week Low | $54.51 | $58.33 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $44.06B | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLEX trades at $110.88, down 5.42% over the past day, amid a broader market pullback. The stock maintains a bullish technical trend with strong analyst support, including a consensus price target of $147.50. Recent acquisitions like EPC Power and the planned spin-off of Axiom highlight strategic moves to capitalize on AI data center and power infrastructure growth. Fundamentals show solid profitability with a net income margin of 3.32% and revenue growth to $29.3B projected for 2026.
The outlook for FLEX is positive, driven by expansion in AI infrastructure and consistent earnings beats. Investment opportunities include potential upside from the Axiom spin-off and continued demand in cloud and power sectors. Key risks involve integration challenges from acquisitions, competitive pressures, and market volatility affecting valuation multiples.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flex Ltd
Flex provides design, engineering, manufacturing, supply chain, and logistics services for technology products. It serves industries including cloud, data centers, communications, automotive, healthcare, and industrials.
Read more on FLEX →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
